Science | Age Revive
This page explains protocol architecture, ingredient rationale, delivery, testing, and evidence summaries. Educational information — not medical advice.
Understanding the evidence
Not all evidence is equal. Labels clarify what level of research supports each ingredient.
- Human data
- Published research in human subjects evaluating safety, biomarkers, or functional endpoints.
- Emerging human data
- Early-stage human research or observational data. Promising but not yet robust.
- Mechanistic / preclinical
- Cell, animal, or in vitro models establishing biological plausibility.
- Formulation choice
- Design decision based on delivery, stability, or absorption logic.
Trust markers
- Clinically studied compounds: Selected for mechanism relevance and human research where available.
- Transparent dosing: Full label disclosure. No proprietary blends.
- Delivery designed for biology: Enteric protection where stomach exposure compromises usefulness.
- Third-party testing: Purity, potency, and contaminants verified by independent labs.
Three layers, one system
CELLUNAD+
Daily NAD+ and metabolic foundation. Supports NAD+ regeneration and mitochondrial energy metabolism with methylation co-factor support.
Cadence: 2 capsules daily · Key: 500 mg NR, TMG, 5-MTHF, B12, P-5-P, R-Lipoic Acid, Apigenin
CELLUBIOME
Gut barrier and mitochondrial renewal support. Pairs mitochondrial recycling support (mitophagy) with gut barrier support via bioavailable butyrate.
Cadence: 2 enteric capsules daily · Key: 500 mg Urolithin A, 500 mg Tributyrin, enteric-coated delivery
CELLUNOVA
7-day monthly renewal protocol. A periodic protocol supporting autophagy-related pathways, mitochondrial resilience, and exposure to senescence research compounds.
Cadence: 5 capsules daily × 7 days, monthly · Key: Spermidine, trans-resveratrol, EGCG, quercetin, fisetin, NAC, PQQ, Ca-AKG
Our standards
- Dose: We prioritize doses that match or align with published human research when available, and we state doses clearly on the label.
- Delivery: If a compound needs to reach the intestine intact, delivery is not optional. Enteric protection is used when stomach exposure reduces effectiveness.
- Mechanism: We formulate around biological pathways, not buzzwords: NAD+ metabolism, mitophagy, gut barrier integrity, autophagy-related processes.
- Transparency: No proprietary blends. Every ingredient and dose is listed so you can evaluate the protocol directly.
- Testing: Third-party testing for purity, potency, and contaminants. We prefer measurable trust over marketing trust.
Formulation logic
CELLUNAD+
What it is for: Daily NAD+ restoration. NR (Nicotinamide Riboside) is a precursor used by cells to synthesize NAD+, a coenzyme central to cellular energy metabolism. The formula includes methylation co-factors (TMG, 5-MTHF, B12, P-5-P) because NAD+ metabolism intersects with methylation pathways.
What it is not: Not a stimulant. Not a single-ingredient stack. Not designed for transient energy spikes.
How it is used: 2 capsules daily. Evaluate over 8–12 weeks of consistent use. Consistency matters more than timing.
Formulation rationale: NR dose (500 mg) aligns with published human studies. Methylation co-factors are included to support balanced pathway activity rather than isolated precursor loading.
Confidence note: NR has published human research for NAD+ elevation and tolerability. Co-factors like TMG and active B vitamins have well-established biochemistry. Apigenin and R-Lipoic Acid have mechanistic support with varying human evidence by endpoint.
CELLUBIOME
What it is for: Gut barrier support and mitochondrial renewal. Urolithin A supports mitophagy pathways. Tributyrin delivers bioavailable butyrate downstream to support gut barrier integrity.
What it is not: Not a probiotic. Not intended to treat gut disease. It is a targeted compound approach for gut barrier integrity and mitochondrial maintenance pathways.
How it is used: 2 enteric capsules daily. Enteric protection ensures the contents reach the intestine intact.
Formulation rationale: Urolithin A dose (500 mg) matches published human studies. Tributyrin is used instead of direct butyrate because butyrate is unstable upstream. Enteric protection is a deliberate design choice — without it, the formula would not match its intent.
Confidence note: Urolithin A has published human research on safety and mitochondrial biomarkers. Butyrate has strong mechanistic literature (cell and animal models). Tributyrin-specific evidence includes in vitro GI simulation models — not yet clinical outcomes trials.
CELLUNOVA
What it is for: Periodic support for autophagy-related pathways, exposure to senescence research compounds, and mitochondrial resilience during a defined protocol window.
What it is not: Not daily. Not a maintenance supplement. Not a senolytic drug protocol. Referencing senescence research does not mean identical outcomes from different protocols, doses, or combinations.
How it is used: 5 capsules daily for 7 consecutive days, repeated monthly. Periodic format reflects how these pathways are explored in research settings.
Formulation rationale: Combines autophagy support (spermidine, resveratrol, EGCG), senescence research compounds (quercetin, fisetin), and mitochondrial resilience (NAC, PQQ, astaxanthin, Ca-AKG). Contains wheat (spermidine source).
Confidence note: Spermidine has emerging human data, often observational. Quercetin and fisetin appear in senescence research — human clinical data is early and often involves combination protocols (e.g., D+Q). NAC and EGCG have broader human evidence. PQQ and Ca-AKG evidence varies by endpoint.
Evidence and dosing
CELLUNAD+
Daily NAD+ foundation using NR with co-factor support for balanced metabolism.
| Ingredient | Dose | Evidence | Purpose |
|---|---|---|---|
| Nicotinamide Riboside (NR) | 500 mg | Human data | Used in published human studies evaluating NAD+ elevation and tolerability. (See Martens 2018; Trammell 2016.) |
| R-Lipoic Acid | 200 mg | Emerging human data | Mitochondrial cofactor studied for oxidative balance and metabolic support. (Human literature varies by indication and dose.) |
| Apigenin | 100 mg | Mechanistic / preclinical | Supportive flavone studied for cellular stress-response signaling. (Evidence base varies by endpoint.) |
| Betaine (TMG) | 250 mg | Human data | Co-factor support for methylation pathways associated with NAD+ metabolism. |
| P-5-P | 10 mg | Human data | Active B6 form supporting amino acid and methylation-related enzymatic processes. |
| 5-MTHF | 400 mcg DFE | Human data | Active folate form used to support methylation pathways. (DFE = dietary folate equivalents.) |
| Methylcobalamin | 1,000 mcg | Human data | Active B12 form used in methylation support stacks. |
| BioPerine | 5 mg | Formulation choice | Included to support absorption of select compounds. |
CELLUBIOME
Gut-mitochondria interface: mitophagy support paired with butyrate delivery and gut barrier support.
| Ingredient | Dose | Evidence | Purpose |
|---|---|---|---|
| Urolithin A | 500 mg | Human data | Dose aligned with published human studies evaluating safety and mitochondrial-related biomarkers. (See Andreux 2019.) |
| Tributyrin | 500 mg | Mechanistic / preclinical | Butyrate precursor designed to resist gastric conditions and deliver butyrate downstream. (Butyrate barrier literature includes cell and animal models; tributyrin research includes in vitro GI simulation models.) |
| Enteric protection | Formulation | Formulation choice | Used when upstream digestion reduces the fraction reaching the intestine intact. (Design choice, not an ingredient.) |
CELLUNOVA
Periodic 7-day protocol combining autophagy support, senescence research compounds, and mitochondrial resilience support.
| Ingredient | Dose | Evidence | Purpose |
|---|---|---|---|
| NAC | 600 mg | Human data | Commonly used to support glutathione-related antioxidant pathways. |
| Trans-Resveratrol | 500 mg | Emerging human data | Studied for cellular stress-response signaling; evidence varies by endpoint. |
| Quercetin | 500 mg | Emerging human data | Studied in senescence research; human data for senolytics is early and often in combination protocols. (See Hickson 2019 (D+Q) for context.) |
| Fisetin | 100 mg | Mechanistic / preclinical | Studied in senescence-related research and preclinical models. (Evidence in humans is still emerging.) |
| Green Tea Extract (50% EGCG) | 300 mg | Human data | Studied for cellular stress-response signaling and metabolic support. |
| Spermidine (wheat germ) | 15 mg | Emerging human data | Linked to autophagy-related pathways across model systems; human data often observational or indirect. (Contains wheat.) |
| Astaxanthin | 4 mg | Human data | Studied for oxidative defense support. |
| PQQ | 10 mg | Mechanistic / preclinical | Studied in mitochondrial biogenesis signaling contexts; evidence varies by endpoint. |
| Ca-AKG | 300 mg | Emerging human data | Studied in metabolic contexts; evidence varies by endpoint. |
| BioPerine | 5 mg | Formulation choice | Included to support absorption of select compounds. |
Glossary
- NAD+
- Nicotinamide adenine dinucleotide. A coenzyme involved in cellular energy metabolism and multiple enzymatic processes tied to cellular maintenance.
- NR (Nicotinamide Riboside)
- A precursor used by cells to synthesize NAD+. Human studies have evaluated NR supplementation for NAD+ elevation and tolerability.
- Mitochondria
- Organelles involved in energy production and metabolic signaling. Mitochondrial function influences cellular resilience.
- Mitophagy
- A cellular process involved in recycling damaged mitochondria as part of broader cellular maintenance systems.
- Butyrate
- A short-chain fatty acid produced by gut microbes and also delivered via precursors. Studied for gut barrier and metabolic signaling roles.
- Gut barrier integrity
- Structural and functional properties of the intestinal lining, including tight junction regulation and mucus layer support.
- Autophagy
- A cellular recycling process that helps clear damaged components and supports cellular homeostasis.
- Cellular senescence
- A state where cells stop dividing and can change signaling output. Human interventions targeting senescence are an active research area.
- Enteric protection
- A formulation approach that protects capsule contents from stomach acid so they release further downstream in the digestive tract.
Science FAQ
- Is this page medical advice?
- No. This is educational information about ingredients, dosing, and formulation choices. It is not medical advice.
- What does "clinically studied" mean here?
- It means the ingredient has published human research evaluating safety, biomarkers, or functional endpoints. It does not guarantee a specific outcome for every individual.
- Do you use proprietary blends?
- No. We disclose every ingredient and dose so you can evaluate the protocol directly.
- Do you publish third-party testing?
- We third-party test for purity, potency, and contaminants. COAs can be made available through support depending on lot and product.
- Why does delivery matter?
- Some compounds are degraded or absorbed too early. Enteric protection is used when the goal is to reach the intestines intact.
- How do the three products fit together?
- CELLUNAD+ is a daily NAD+ foundation, CELLUBIOME supports gut-mitochondria signaling stability, and CELLUNOVA is a periodic 7-day monthly reset protocol.
- How long should I evaluate a protocol?
- Most people assess meaningful changes after 8 to 12 weeks of consistent use for daily products.*
- Any safety notes?
- Consult your healthcare provider before use if you are pregnant, nursing, on medication, or managing a medical condition. CELLUNOVA contains wheat (spermidine source).
References
NAD+ / Nicotinamide Riboside
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications (2018).
Human trial: NR safety, tolerability, and NAD+ elevation.
- Trammell SAJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications (2016).
Human and preclinical: oral bioavailability of NR.
Gut barrier / Butyrate / Urolithin A
- Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism (2019).
Human trial: Urolithin A safety and mitochondrial biomarkers.
- Peng L, et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via AMPK in Caco-2 monolayers. Journal of Nutrition (2009).
Cell model: butyrate and barrier mechanism.
- Donohoe DR, et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabolism (2011).
Mechanistic: microbial metabolites and colonocyte mitochondria.
- Duysburgh C, et al. Tributyrin (CoreBiome) modulates butyrate levels and barrier function in vitro GI simulation models. Frontiers in Nutrition (2025).
In vitro simulation model, not a clinical outcomes trial.
Autophagy / Spermidine / Senescence
- Hofer SJ, et al. Spermidine is essential for fasting-mediated autophagy and longevity. Nature Cell Biology (2024).
Mechanistic: spermidine and autophagy pathways.
- Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in diabetic kidney disease. EBioMedicine (2019).
Context: D+Q combination research, not quercetin alone.
General / Consensus
- Salminen S, et al. ISAPP consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology and Hepatology (2021).
Consensus: postbiotic definitions and scope.
Build your protocol
Start with the daily foundation, add gut-mitochondria stability, then layer in a periodic reset. Simple structure. Clear intent.
- Shop CELLUNAD+ - NAD+ restoration with methylation co-factor support.
- Shop CELLUBIOME - Mitophagy support plus butyrate delivery for gut barrier integrity.
- Shop CELLUNOVA - 7-day protocol supporting autophagy-related pathways and mitochondrial resilience.